GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (NAS:ANL) » Definitions » EPS (Basic)

ANL (Adlai Nortye) EPS (Basic) : $-2.12 (TTM As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Adlai Nortye EPS (Basic)?

Adlai Nortye's basic earnings per share (Basic EPS) for the three months ended in Jun. 2024 was $0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2024 was $-2.12.

Adlai Nortye's EPS (Diluted) for the three months ended in Jun. 2024 was $0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $-2.12.

Adlai Nortye's EPS without NRI for the three months ended in Jun. 2024 was $0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2024 was -2.12.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Adlai Nortye EPS (Basic) Historical Data

The historical data trend for Adlai Nortye's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adlai Nortye EPS (Basic) Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23
EPS (Basic)
-1.54 -1.59 -7.26

Adlai Nortye Quarterly Data
Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23 Jun24
EPS (Basic) Get a 7-Day Free Trial - -0.40 -1.72 - -

Adlai Nortye EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Adlai Nortye's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-104.871-0)/14.447
=-7.26

Adlai Nortye's Basic EPS for the quarter that ended in Jun. 2024 is calculated as

Basic EPS (Q: Jun. 2024 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(0-0)/26.128
=0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adlai Nortye  (NAS:ANL) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Adlai Nortye EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Adlai Nortye's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Adlai Nortye Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (NAS:ANL) » Definitions » EPS (Basic)
Comparable Companies
ABOS IVVD CLSD MNOV AVTE ACRV NTRB EPIX IGMS DOMH VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
685 US Highway 1, New Jersey Biotechnology Development Center, 2nd floor, North Brunswick, NJ, USA, 08902
Website
https://www.adlainortye.com
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.